{"Q": 1, "answer": "no", "rationale": "The segment describes a vaccine deal but contains no intensifier or comparative modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_14728", "batch_size": 200, "batch_pos": 15, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain high-potency verbs, potent metaphors, superlatives, intensifiers, or critical alert phrases.", "method": "llm_batch", "batch_id": "batch_2_19360", "batch_size": 200, "batch_pos": 5, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 3, "answer": "no", "rationale": "No moderate verb from the Q3 list is present.", "method": "llm_batch", "batch_id": "batch_3_16412", "batch_size": 200, "batch_pos": 154, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_13024", "batch_size": 200, "batch_pos": 152, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 5, "answer": "no", "rationale": "Reports details of vaccine deal without explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_4640", "batch_size": 200, "batch_pos": 149, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 6, "answer": "no", "rationale": "Segment reports securing vaccine doses and options but lacks a minimiser + scale contrast.", "method": "llm_batch", "batch_id": "batch_6_20396", "batch_size": 200, "batch_pos": 117, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_18940", "batch_size": 200, "batch_pos": 101, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 8, "answer": "yes", "rationale": "The segment describes securing vaccine doses (preparedness/stockpiling): 'deal secures up to 665,000 doses... includes an option for a further 40 million vaccines'.", "method": "llm_batch", "batch_id": "batch_8_4296", "batch_size": 200, "batch_pos": 137, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
